List of Microbiome Companies in Australia - 4

Anatara Lifesciences is developing evidence-based solutions for gastrointestinal diseases in humans and animals. GaRP is the working name for Anatara’s evidence based complementary medicines using unique formulations of bromelain, an enzyme extracted from pineapple stems along with other synergistic GRAS components. The combination and coating of these GaRP components have a beneficial effect on the physiology of the gastrointestinal lining, a positive influence on the microbiome (homeostasis & metabolites) and allows absorption of components in targeted areas of the gastrointestinal tract. GaRP’s multimodal activity provides a versatility for tailoring the components to various indications. Human Applications GaRP's human formulation is a microbiome-targeted multi-component complementary medicine that has been designed to address the primary underlying factors associated with gastrointestinal disorders such as IBS and IBD. Our formulation is positioned as an adjunct to existing therapies and is currently being tested in a double-blinded, placebo-controlled human clinical trial for safety and efficacy. For further information on our human development plans, visit our webpage: https://anataralifesciences.com/products-pipeline/human-applications/. Animal Applications Anatara developed Detach® for the control of scour (diarrhoea) in pigs which was approved the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach® has been shown to reduce post-weaning diarrhoea and provide similar protection to antimicrobial agents, such as zinc oxide. BONIFF is a revised formulation of Detach® that can be applied to dry feed for piglets after weaning for a simplified feeding process. ANR-pf is a proprietary enriched formulation for poultry in water, providing a quick and flexible dosing method on-farm. For further information on our Detach® development plans, visit our webpage: https://anataralifesciences.com/products-pipeline/animal-applications/.

BiomeBank's mission is to treat and prevent disease by restoring gut microbial ecology

Microba Life Sciences is a precision microbiome company driven to advance health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

We are a biopharmaceutical research and production company, based on the Sunshine Coast, Queensland. Established in 2012, we research, develop and produce high-quality, innovative, medical grade biopharmaceuticals based on the latest scientific research. Servatus has two drug research platforms: Engineered proteins for the treatment of autoimmune diseases, and microbial biotherapeutics for the treatment of inflammatory conditions and bacterial infections. Our protein research focuses on improving specific characteristics of existing therapeutic proteins. We carefully select proteins with clear clinical utility, and through rational redesign of key features, we improve bioavailbility and biological potency. We then rapidly clone and express the proteins in amounts suitable for clinical use, thus providing faster, more effective treatment of chronic auto immune diseases, such as rheumatoid arthritis and psoriasis, with fewer undesirable side effects. In parallel with our protein work, we also develop live microbial biotherapeutic treatments for microbiome-associated conditions, including but not limited to inflammatory bowel disease (IBD), arthritis, atopic dermatitis, and gastrointestinal infections (for example, C. diff and H.pylori infections). We utilise bacterial strains that have not been widely employed previously, but have demonstrated bioactive properties in the latest scientific research. These bacteria have been shown to inhibit pathogenic bacterial growth and infection, modulate immune responses, and regulate inflammatory signals. Bacterial candidates are developed to act directly at specific sites to treat specific ailments and diseases. Servatus currently holds patents for numerous microbial biotherapeutics and engineered proteins for autoimmune disease treatments Servatus Ltd derives its name from the patron saint St Servatus, a 4th century churchman and diplomat, who was invoked as a saint for his healing powers for a range of ailments. #biotech